Loading…

Loading grant details…

Completed HORIZON European Commission

Disruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery

€3.56M EUR

Funder European Commission
Recipient Organization Crannmed Ltd
Country Ireland
Start Date May 01, 2022
End Date Nov 30, 2024
Duration 944 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190167448
Grant Description

EmboSure is a breakthrough treatment for Knee Osteoarthritis.

It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5-years.

The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed.

The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body.

The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee.

As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.

All Grantees

Crannmed Ltd

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant